Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2022
Pralsetinib for treating advanced RET fusion positive non-small-cell lung cancer
3 August 2022 - NICE has published evidence-based recommendations on the use of pralsetinib (Gavreto) for the treatment of adults ...
Posted by Michael Wonder on 27 Jul 2022
Duvelisib for patients with chronic lymphocytic leukaemia
27 July 2022 - NICE has published a final technology appraisal for duvelisib for the treatment of patients with relapsed ...
Posted by Michael Wonder on 14 Jul 2022
Breakthrough treatment to boost life chances for hundreds of people with respiratory cancer
14 July 2022 - The first new mesothelioma treatment to be approved in nearly 15 years will be made available ...
Posted by Michael Wonder on 14 Jul 2022
Thousands of patients to benefit as NHS marks 100th fast tracked cancer drug
14 July 2022 - Thousands of people a year with advanced breast cancer will benefit from a life extending drug ...
Posted by Michael Wonder on 14 Jul 2022
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
14 July 2022 - An agreement with the companies on the price of two breast cancer treatments, Piqray and Trodelvy, has ...
Posted by Michael Wonder on 08 Jul 2022
NICE recommends Opdivo as post-surgery treatment
8 July 2021 - The therapy will be used for specific muscle invasive urothelial cancer patients ...
Posted by Michael Wonder on 30 Jun 2022
Zanubrutinib for the treatment of adults with Waldenström’s macroglobulinaemia
29 June 2022 - NICE has published a second appraisal consultation document on the use of zanubrutinib for the treatment ...
Posted by Michael Wonder on 17 Jun 2022
NICE recommends new targeted treatment for early breast cancer
16 June 2022 - NICE has provisionally approved a new treatment for early breast cancer that it says will benefit ...
Posted by Michael Wonder on 15 Jun 2022
Another week, another terminated NICE appraisal
15 June 2022 - It should not come as a surprise that it is for a cancer medicine. ...
Posted by Michael Wonder on 26 May 2022
NICE recommends Libtayo (cemiplimab) for routine NHS commissioning as the first and only systemic treatment for advanced CSCC in England
25 May 2022 - NICE has published a positive Final Appraisal Determination recommending Libtayo (cemiplimab) as the first and only ...
Posted by Michael Wonder on 25 May 2022
New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE
25 May 2022 - An estimated 100 people per year with triple negative breast cancer that has spread to other ...
Posted by Michael Wonder on 24 May 2022
NICE doesn’t recommend ibrutinib for those with Waldenstrom’s macroglobulinaemia
23 May 2022 - Ibrutinib, a drug used to treat Waldenström’s macroglobulinaemia, is not being recommended by NICE in England ...
Posted by Michael Wonder on 16 May 2022
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS
16 May 2022 - Durvalumab recommended as an option for treating non-small-cell lung cancer. ...
Posted by Michael Wonder on 14 May 2022
Hundreds of patients to get life-extending lung cancer drug on the NHS
13 May 2022 - Hundreds of people with a form of the most common form of lung cancer could survive ...
Posted by Michael Wonder on 11 May 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
11 May 2022 - NICE has published evidence based recommendations on the use of avelumab for adults with locally advanced ...